Anand P Jillella, Martha L Arellano, Manila Gaddh, Amy A Langston, Leonard T Heffner, Elliott F Winton, Morgan L McLemore, Chao Zhang, Catherine R Caprara, Kathryn S Simon, Sheldon L Bolds, Stephanie DeBragga, Prachi Karkhanis, Shruthi H Krishnamurthy, Jose Tongol, Mohamed M El Geneidy, Asim Pati, Jonathan M Gerber, Michael R Grunwald, Jorge Cortes, Asad Bashey, Robert K Stuart, Vamsi K Kota
PURPOSE: Acute promyelocytic leukemia (APL) is a curable leukemia with > 90% survival in clinical trials. Population-based studies from Sweden and US SEER data have shown long-term survival rates of 62% and 65.7%, with the lower rate being from a higher percentage of early deaths. METHODS: In this prospective, multicenter trial, we developed a simplified algorithm that focused on prevention and early treatment of the three main causes of death: bleeding, differentiation syndrome, and infection...
October 30, 2020: JCO oncology practice